Business Description
IQVIA Holdings Inc
NAICS : 621399
SIC : 8099
ISIN : US46266C1053
Total Employee Number:
94,000Compare
Compare
Traded in other countries / regions
IQV.USA0JDM.UKI1QV34.BrazilIQV.MexicoQTS.Germany1IQV.ItalyIQVH.Austria Index Membership
S&P 500Russell 1000Russell 3000MSCI World Index IPO Date
2013-05-09Description
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | 0.21 | |||||
Debt-to-Equity | 2.63 | |||||
Debt-to-EBITDA | 4.6 | |||||
Interest Coverage | 3.06 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.22 | |||||
Beneish M-Score | -2.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.5 | |||||
3-Year EBITDA Growth Rate | 9.4 | |||||
3-Year EPS without NRI Growth Rate | 5.5 | |||||
3-Year FCF Growth Rate | 12.4 | |||||
3-Year Book Growth Rate | 7.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.78 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.27 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.68 | |||||
9-Day RSI | 69.44 | |||||
14-Day RSI | 69.63 | |||||
3-1 Month Momentum % | 22.11 | |||||
6-1 Month Momentum % | 28.29 | |||||
12-1 Month Momentum % | 23.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.71 | |||||
Quick Ratio | 0.71 | |||||
Cash Ratio | 0.24 | |||||
Days Sales Outstanding | 33.67 | |||||
Days Payable | 96.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3 | |||||
Shareholder Yield % | -0.41 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 32.97 | |||||
Operating Margin % | 13.88 | |||||
Net Margin % | 8.1 | |||||
EBITDA Margin % | 20.77 | |||||
FCF Margin % | 12.86 | |||||
OCF Margin % | 16.6 | |||||
ROE % | 22.3 | |||||
ROA % | 4.68 | |||||
ROIC % | 7.08 | |||||
3-Year ROIIC % | 7.96 | |||||
ROC (Joel Greenblatt) % | 284.38 | |||||
ROCE % | 11.14 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 33.22 | |||||
Forward PE Ratio | 18.52 | |||||
PE Ratio without NRI | 21.47 | |||||
Shiller PE Ratio | 50.58 | |||||
Price-to-Owner-Earnings | 22.75 | |||||
PEG Ratio | 1.72 | |||||
PS Ratio | 2.68 | |||||
PB Ratio | 7.14 | |||||
Price-to-Free-Cash-Flow | 20.91 | |||||
Price-to-Operating-Cash-Flow | 16.19 | |||||
EV-to-EBIT | 24.89 | |||||
EV-to-Forward-EBIT | 19.63 | |||||
EV-to-EBITDA | 16.54 | |||||
EV-to-Forward-EBITDA | 14.08 | |||||
EV-to-Revenue | 3.44 | |||||
EV-to-Forward-Revenue | 3.16 | |||||
EV-to-FCF | 26.72 | |||||
Price-to-GF-Value | 1.08 | |||||
Price-to-Projected-FCF | 1.52 | |||||
Price-to-DCF (Earnings Based) | 0.75 | |||||
Price-to-DCF (FCF Based) | 0.89 | |||||
Price-to-Median-PS-Value | 1.01 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.27 | |||||
Earnings Yield (Greenblatt) % | 4.02 | |||||
FCF Yield % | 4.96 | |||||
Forward Rate of Return (Yacktman) % | 13.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:IQV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IQVIA Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 16,983 | ||
| EPS (TTM) ($) | 8.06 | ||
| Beta | 1.0883 | ||
| 3-Year Sharpe Ratio | 0.21 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 40.94 | ||
| 14-Day RSI | 69.63 | ||
| 14-Day ATR ($) | 7.652192 | ||
| 20-Day SMA ($) | 254.0105 | ||
| 12-1 Month Momentum % | 23.97 | ||
| 52-Week Range ($) | 154.5 - 271.7999 | ||
| Shares Outstanding (Mil) | 164.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IQVIA Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IQVIA Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-17 | In 164 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-05 09:00 | In 153 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-05 | In 152 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-28 09:00 | In 53 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 52 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-28 09:00 | 213.22 (+2.84%) | ||
| Second quarter earnings results for 2026 | 2026-07-28 | 213.22 (+2.84%) | ||
| Jeeries Global Healthcare Conference | 2026-06-03 09:20 | 180.64 (-2.36%) | ||
| Bank of America Health Care Conference | 2026-05-13 13:40 | 175.06 (+0.62%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 09:00 | 160.94 (+1.54%) |
Show
Entries
IQVIA Holdings Inc Frequently Asked Questions
What is IQVIA Holdings Inc(IQV)'s stock price today?
The current price of IQV is $267.77. The 52 week high of IQV is $271.80 and 52 week low is $154.50.
When is next earnings date of IQVIA Holdings Inc(IQV)?
The next earnings date of IQVIA Holdings Inc(IQV) is 2026-10-28 Est..
Does IQVIA Holdings Inc(IQV) pay dividends? If so, how much?
IQVIA Holdings Inc(IQV) does not pay dividend.
Guru Commentaries on NYSE:IQV
2026 Q1
Hardman Johnston Global Advisors LLC
· 77 holdings
What the manager wrote
IQVIA Holdings Inc. is a critical partner to the biotech and pharmaceutical industries. Despite facing pressure from fears of AI disruption and rising interest rates affecting smaller customers, we believe the collection of capabilities and assets this company holds makes them a powerful player in their industry. The argument that AI will help both them and their customers further supports our positive outlook. We continue to think that the long-term prospects for IQVIA remain strong.
Artemis Us Select Fund
Bullish
2026 Q1
What the manager wrote
IQVIA provides clinical-research services and healthcare data to the life sciences industry. The shares were caught up in a sell-off driven by concerns AI would disrupt data-oriented businesses. However, we believe widespread disruption to the drug-development process is unlikely in the medium term and the company should benefit from a recovery in demand.
Press Release
Articles on IQVIA Holdings Inc
Headlines
See More- 1
Sep 02, 2026
Tempus AI gains as Cantor issues new Overweight on Data and applications segment
Seeking Alpha • 10:18am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers